UiPath Announces Fiscal First Quarter 2022 Financial Results Conference Call
- Dow, S&P futures inch higher as banks, energy stocks jump
- EV Company Polestar To Go Public Via $20 Billion SPAC Deal
- Amazon (AMZN) Price Target Lowered at Morgan Stanley Amid Rising Logistics Workforce Costs, Analyst Expects Stock to be Range Bound in Near Term
- Acceleron Pharma (XLRN) Said in Advanced Talks for $11 Billion Sale - Bloomberg (Earlier)
- Brent oil nears $80 a barrel amid supply constraints
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
NEW YORK--(BUSINESS WIRE)-- UiPath, Inc. (NYSE: PATH), a leading enterprise automation software company, today announced it will report financial results for its fiscal first quarter 2022 ended April 30, 2021 after the market close on Tuesday, June 8, 2021. Management will host a conference call and webcast to discuss the Company's financial results at 5:00 pm ET.
UiPath Fiscal First Quarter 2022 Financial Results Conference Call
When: Tuesday, June 8, 2021
Time: 5:00 pm ET
Conference ID: 13719454
Live Call: 1-877-407-8309 (US/Canada Toll-Free) or 1-201-689-8057 (Toll)
Replay: 1-877-660-6853 (US Toll-Free), 201-612-7415 (Toll)
(The replay will be available approximately two hours after the completion of the live call until 11:59 pm ET on June 22, 2021)
UiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.
Source: UiPath, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rocky Mountain Chocolate Factory Comments on Proxy Advisory Reports
- GoGlobal Launches in Brazil and Appoints Employer of Record Expert Ana Vizzotto as Director
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastati
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!